S. H. Bachow

Emerging therapies in relapsed and refractory peripheral T-cell lymphoma.

O. O’Connor, S. H. Bachow, 2015, Clinical advances in hematology & oncology : H&O.

What appears safe is sometimes not: a reason for caution.

N. Lamanna, S. H. Bachow, 2016, Blood.

Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients

B. Cheson, D. Porter, C. Nabhan, 2016 .

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

B. Cheson, D. Brander, S. Schuster, 2018, Haematologica.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

B. Cheson, D. Porter, A. Evens, 2016, Blood.

Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting

N. Lamanna, S. H. Bachow, 2016, Current Hematologic Malignancy Reports.

Vitamin D and Cancer—A Review

C. Friedman, S. H. Bachow, 2013 .

Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study

B. Cheson, D. Porter, A. Evens, 2015 .

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

B. Cheson, K. Foon, C. Nabhan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.